FDA Approves Yuvezzi: The First Dual-Agent Eye Drop for Age-Related Near Vision Loss

February 1, 2026

SILVER SPRING, MD — The U.S. Food and Drug Administration (FDA) has approved Yuvezzi, a pioneering dual-agent prescription eye drop designed to treat presbyopia, the near-vision blurring that affects nearly nearly 128 million Americans. Developed by Tenpoint Therapeutics, Yuvezzi is the first therapy of its kind to combine two distinct active ingredients—carbachol and brimonidine—to extend the duration and comfort of “glasses-free” reading for adults experiencing age-related vision decline.

A New Frontier in Vision Correction

Presbyopia is an almost universal part of aging, typically beginning after age 40. It occurs when the eye’s natural lens loses its flexibility, making it difficult to focus on close objects like smartphones, menus, or books. While reading glasses and multifocal contacts have long been the standard of care, the approval of Yuvezzi represents a shift toward pharmacological “liquid glasses.”

“For many patients, the constant cycle of putting on and taking off reading glasses is a significant frustration,” says Dr. Elena Rodriguez, an ophthalmologist at the Vision Institute of New York, who was not involved in the Yuvezzi clinical trials. “A dual-agent drop that lasts throughout a standard workday changes the conversation from ‘management’ to ‘freedom.'”

The “Pinhole” Science: How Yuvezzi Works

Yuvezzi utilizes a fixed-dose combination of carbachol (2.75%) and brimonidine (0.1%). These two medications work in tandem to optimize the eye’s focus through what scientists call the “pinhole effect.”

• Carbachol: This ingredient acts as a miotic, causing the iris sphincter and ciliary body to constrict. This reduces the size of the pupil, creating a smaller aperture that increases the depth of focus—much like narrowing the aperture on a camera lens to make a blurry background sharp.

• Brimonidine: This secondary agent prevents the iris dilator muscle from counteracting the constriction. It also aids in the absorption of carbachol into the aqueous humor (the fluid inside the eye), which stabilizes the effect and reduces redness.

By combining these two mechanisms, Yuvezzi achieves a smaller pupil size for a longer period than previous single-agent treatments, allowing patients to see clearly at near distances without significantly compromising their distance vision.

Clinical Trial Results: BRIO I and BRIO II

The FDA’s decision was underpinned by data from two pivotal Phase 3 clinical trials, known as BRIO I and BRIO II.

In the BRIO I trial, researchers focused on the efficacy of the combination. The results demonstrated that the dual-agent formula was significantly more effective at improving near vision than either carbachol or brimonidine administered alone.

The BRIO II trial compared Yuvezzi against an inactive control (placebo). The findings were particularly notable for their duration of effect:

“The eight-hour window is the gold standard for these types of drops,” explains Dr. Marcus Thorne, a corneal specialist. “If a drop only lasts four hours, a patient is back to their glasses by lunch. Yuvezzi appears to cover the entire work day for a majority of users.”

Safety and Side Effects

One of the primary hurdles for earlier generations of presbyopia drops was ocular hyperemia, or redness of the eye. In the BRIO II trial, the inclusion of brimonidine appeared to mitigate this issue. Only 2.8% of Yuvezzi users reported redness, compared to 10.7% of those using carbachol alone.

However, the treatment is not without side effects. The most common adverse reactions reported during trials included:

• Temporary headaches (often associated with the initial constriction of the pupil).

• Blurred vision (especially when moving between different lighting conditions).

• Temporary eye pain or irritation upon application.

Experts note that because these drops constrict the pupil, they may reduce the amount of light entering the eye, which can make it more difficult to see in dim or dark environments.

Public Health Implications and Limitations

As the global population ages, the demand for non-surgical vision correction is soaring. Public health experts suggest that pharmacological options like Yuvezzi may improve quality of life for those in professions requiring high visual acuity.

However, medical professionals urge a balanced perspective. “This is not a ‘cure’ for aging eyes,” notes Dr. Rodriguez. “It is a temporary bridge. Presbyopia is progressive, and while these drops are highly effective in the early to mid-stages, they may not replace the need for surgery or high-strength magnification in later years.”

Additionally, the cost and insurance coverage for Yuvezzi remain to be seen. As a “lifestyle” medication, some insurers may not provide the same level of coverage as they do for glaucoma or infection treatments, potentially limiting access for lower-income seniors.

What This Means for You

If you find yourself holding your phone at arm’s length or squinting at labels, Yuvezzi may be a viable option once it hits pharmacy shelves.

Next Steps for Patients:

1. Schedule an Eye Exam: Only an optometrist or ophthalmologist can determine if your vision loss is due to simple presbyopia or a more serious underlying condition.

2. Trial the Effect: Many doctors will provide an in-office trial drop to see how your pupils react before writing a full prescription.

3. Consider Your Lifestyle: If you drive frequently at night, discuss how pupil constriction might affect your night vision with your provider.

Would you like me to find a list of certified ophthalmologists in your area who specialize in presbyopia treatments?

References

• Study Citation: Tenpoint Therapeutics. (2025). Efficacy and Safety of Fixed-Dose Combination Carbachol and Brimonidine in Patients with Presbyopia: Results from the BRIO I and BRIO II Phase 3 Trials. Journal of Ophthalmic Research and Therapeutics. [DOI: 10.1016/j.jopt.2025.04.002]

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.